Bristol-Myers Squibb's melanoma drug Yervoy and clot-fighter Eliquis helped boost its earnings past analyst forecasts, with $333 million in profits on $3.9 billion in revenue.
Bristol-Myers Squibb plans to submit its closely watched cancer candidate nivolumab for FDA approval to treat melanoma next quarter, outpacing analysts' expectations and setting the stage for a duel with Merck's rival drug.
According to a new report from Decision Resources Group, the cancer immunotherapy market is set to balloon from $1.1 billion in 2012 to nearly $9 billion in 2022 in the U.S., France, Germany, Italy, Spain, the U.K. and Japan.
Bristol-Myers Squibb has become the first drugmaker to win regulatory approval for a combination hepatitis C treatment that doesn't require painful injections, picking up a Japanese nod for its all-oral cocktail.
Bristol-Myers Squibb in April quit making injected Coumadin, the form used in the rare cases when patients can't take the oral formulation. But there is still product in the market and and the company is having to recall some of it.
Bristol-Myers Squibb has tapped Duke University's in-house CRO to pitch in on clinical trial transparency, asking the organization's researchers to independently review requests for shared data.
While the debate over how to implement clinical trial data transparency laws rages in Europe, Big Pharma firms continue to roll out their own offerings, with Bristol-Myers Squibb the latest to show its hand. And the U.S. drugmaker has gone further than some of its peers by handing over decision-making powers to a third party and promising to publish full clinical study reports.
Right now, Eliquis, the new-age clot-fighter from Pfizer and Bristol-Myers Squibb, is in third place in a three-horse race. But as it tries to catch up to rivals Pradaxa and Xarelto--not to mention the $3-billion-per-year sales forecasts analysts slapped on it in its early days--a new recommendation for expanded use in Europe should give it a boost.
European regulators are recommending approval for Bristol-Myers Squibb's daclatasvir, an hepatitis C-fighting antiviral that plays a key role in the company's planned combo treatment.
Avista Capital Partners is looking for liquidity in its investment in medical imaging agent provider Lantheus. The company recently filed for a $125 million IPO. The financing would allow Lantheus to repay some of the debt that the private equity firm loaded it up with, in part to pay itself dividends.